Enhancing Chemotherapy Response With Bmi-1 Silencing in Ovarian Cancer

PLoS ONE - United States
doi 10.1371/journal.pone.0017918
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer

Oncologist
Cancer ResearchMedicineOncology
2012English

Epigenetic Silencing of TCEAL7 (Bex4) in Ovarian Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched With Patients Treated With Parenteral Chemotherapy

Anticancer Research
MedicineCancer ResearchOncology
2016English

Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Genetic Polymorphisms and Ovarian Cancer Risk and Response to Paclitaxel/Cisplatin Chemotherapy

Hereditary Cancer in Clinical Practice
OncologyGenetics
2015English

PD-L1 Biology in Response to Chemotherapy in Vitro and in Vivo in Ovarian Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Clinical Response in Patients With Ovarian Cancer Treated With

ecancermedicalscience
Cancer ResearchOncology
2017English

Germline BRCA, Chemotherapy Response Scores, and Survival in the Neoadjuvant Treatment of Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Global Gene Expression Analysis of Early Response to Chemotherapy Treatment in Ovarian Cancer Spheroids

BMC Genomics
BiotechnologyGenetics
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy